Bacteria transmit metformin-associated lifespan extension

  title={Bacteria transmit metformin-associated lifespan extension},
  author={Lesley T. MacNeil and Jonathan D. Schertzer and Gregory R. Steinberg},
  journal={Nature Reviews Endocrinology},
Metformin is the mainstay therapy for type 2 diabetes mellitus. A new study shows that metformin acts directly on gut bacteria to elevate cAMP-induced agmatine production, thereby increasing lipid metabolism and lifespan in model organisms. These data identify links between metformin and gut microbiota that might be important for increasing longevity. 

Figures from this paper

New Insight into Metformin Mechanism of Action and Clinical Application
The evidence linking the effects of metformin on insulin resistance, prediabetes, diabetes, aging, cancer, PCOS, cardiovascular diseases, and neurodegenerative diseases is focused on. Expand
Repurposing drugs to fight aging: The difficult path from bench to bedside
Recent advances and challenges in the field of repurposing widely used conventional pharmaceuticals to target the aging process are summarized and discussed. Expand
Health and Pro-Longevity Interventions
This chapter discusses whether the conventionally used drugs can be repurposed to target the aging process per se and the advances and challenges in this emerging research field are summarized. Expand
Explaining Health Across the Sciences
Health is a key aspect of the fitness of an organism, both in the everyday sense where fitness refers to general functional wellbeing, and in the more particular sense where fitness refers toExpand


Metformin Retards Aging in C. elegans by Altering Microbial Folate and Methionine Metabolism
It is reported that metformin increases lifespan by altering microbial folate and methionine metabolism, consistent with action of this drug as a dietary restriction mimetic. Expand
Metformin as Anti-Aging Therapy: Is It for Everyone?
Before metformin finds its way to mainstay therapy for anti-aging, a more granular understanding of the effects of the drug in humans is needed. Expand
Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus
Despite its position as the first-line drug for treatment of type 2 diabetes mellitus, the mechanisms underlying the plasma glucose level-lowering effects of metformin (1,1-dimethylbiguanide) stillExpand
Metformin Induces a Dietary Restriction–Like State and the Oxidative Stress Response to Extend C. elegans Healthspan via AMPK, LKB1, and SKN-1
It is found that metformin increases nematode healthspan, slowing lipofuscin accumulation, extending median lifespan, and prolonging youthful locomotory ability in a dose-dependent manner, suggesting that met formin may be a plausible pharmacological intervention to promote healthy human aging. Expand
Host-Microbe-Drug-Nutrient Screen Identifies Bacterial Effectors of Metformin Therapy
It is shown that microbes integrate cues from metformin and the diet through the phosphotransferase signaling pathway that converges on the transcriptional regulator Crp, which predicts the production of microbial agmatine, a regulator of met formin effects on host lipid metabolism and lifespan. Expand
Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-α in mice
As met formin modulates multiple components of the incretin axis, and enhances expression of the Glp1r and related insulinotropic islet receptors through a mechanism requiring PPAR-α, metformin may be mechanistically well suited for combination with incretIn-based therapies. Expand
Bi-directional drug-microbiome interactions of anti-diabetics
Understanding this bi-directional drug-microbiome interaction and how it influences the clinical outcomes of antidiabetic drugs can pave the way to develop next-generation strategies to ameliorate diabetes. Expand
Single phosphorylation sites in Acc1 and Acc2 regulate lipid homeostasis and the insulin–sensitizing effects of metformin
It is established that inhibitory phosphorylation of Acc by Ampk is essential for the control of lipid metabolism and, in the setting of obesity, for metformin-induced improvements in insulin action. Expand
Agmatine: clinical applications after 100 years in translation.
This timely review, a concerted effort by 16 independent research groups, draws attention to the substantial preclinical and initial clinical evidence, and highlights challenges and opportunities, for the use of agmatine in treating a spectrum of complex diseases with unmet therapeutic needs. Expand
Metformin increases blood flow and forearm glucose uptake in a group of non-obese type 2 diabetes patients.
It was found that in these participants metformin acts in insulin resistance; it increases glucose muscle uptake and blood flow, and the enhancement of blood flow and lower free fatty acids, not described yet, could be direct effects of the drug or due to reduced glucose toxicity. Expand